Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC

CisionPR Newswire_2.png

VANCOUVER, British Columbia and SAN DIEGO, June 4, 2019 - In March 2018, PhoenixMD and STA Pharmaceutical (WuXi STA) entered into a major manufacturing agreement, and have since produced a multi kilogram drug supply for PMD-026 under GMP manufacturing practices. This represents a significant milestone, accelerating PhoenixMD's Phase I readiness.

Read the story  here